Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas

Neuropathology and Applied Neurobiology

Volumn 24, Issue 5, 1998, Pages 381-388

  Bouvier Labit, C ^a   Chinott, O ^a   Ochit, C ^a   Gambarelli, D ^b   Dufourt, H ^b   Figarella Branger, D ^a  

^a Department of Pathology and Neuropathology ^*  (France)

^b TIMONE HOSPITAL   (France)

Author keywords

Epidermal growth factor receptor; Glioblastomas; Proliferation markers; Tumour suppressor proteins

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CELL DIVISION; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031727188     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2990.1998.00137.x     Document Type: Article

References (46)

1. Andreou J, George AE, Wise A et al. CT prognosis criteria of survival after malignant glioma surgery. A]NR 1983; 4: 488-90
2. Batra SK, Rasheed BKA, Bigner DD. Biology of disease. Oncogenes and anti-oncogenes in human central nervous system tumors. Lab Invest 1994; 71: 621-37
3. Bigner SH, Burger CP, Wong AJ et al Gene amplification in malignant human gliomas: clinical and histopathological aspects. J Neuropathol Exp Neurol 1988; 47: 191-205
4. Bögler 0, Huang HJS, Kleihues P, Cavenee WK. The p53 gene and its role in human brain tumors. Glia 1995; 15: 308-27
5. Bouillot P, Pellissier JF, Devictor B et al. Quantitative imaging of estrogcn and progesterone receptors, p S2, growth fraction (Ki67) immunocytochemical assays in 52 meningiomas: correlation with clinical and morphological data. J Neurosiirg 1994; 81: 765-73
6. Brugal G, Garbay C, Giroud F ft al. A double scanning microphotometer for image analysis: hardware, software and biomédical applications. J Histochem Cytochem 1979; 27: 144-52
7. Burger PC. Scheithauer BW (Eds) Atlas of Tumor Pathology, Tumors of the Central Nervous System: Glioblastoma Multiforme, Armed Forces Institute of Pathology, Bethesda, Maryland, 1994; 199: 49-77
8. Charpin C, Bouvier C, Garcia S et al. Automated and quantitative immunocytochemical assays of Nm23/NDPK protein in breast carcinomas, Int J Cancer 1997: 74:416-20
9. Coons SW, Johnson PC. Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki67 labeling index. J Ncuropathol Exp Neurol 1993: 52: 609-18
10. Cordon-Cardo C. Mutation of cell cycle regulators. Biological and clinical amplifications for human neoplasia. Am J Pathol 1995; 147: 545-60
11. Cunningham JM, Kimmel DVV, Scheithauer BW, O'Fallon JR. Novotmy PJ, Jenkins RB. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg 1987; 86: 121-30
12. Ellison DM, Gatter KC, Steart PV, Lane DP, Weller RO. Expression of the p53 protein in a spectrum of astrocytic tumours. J Pathol 1992; 168: 383-6
13. Figarella-Branger D, Lepidi H, Poncet C et al. Differential expression of cell adhesion molecules (CAM), neural CAM and epithelial cadherin in ependymomas and choroid plexus tumors. Acta Neuropathol 1995; 89: 248-57
14. Figarella-Branger D, Pellissier JF, Bouillot P et al. Expression of NCAM isoforms and epithelial cadherin adhesion molecules in 47 human meningiomas. Correlation with clinical and morphological data. Mod Pathol 1994: 7: 752-61
15. Fischbach AJ, Martz KL, Nelson JS et al. Long term survival in treated anaplasic astrocytomas. A report of combined RT06/ECOG studies. Am }Clin Oncol 1991; 14: 365-70
16. Gerdes J, Lemke H. Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki67. J Immunol 1984; 133: 1710-5
17. Haapasalo H. Isola J, Sallinen P, Kalimo H. Heiin H, Rantala I. Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation. Am J Pathol 1993; 142: 1347-51
18. Hall PA, Lane DP. p53 in tumor pathology: can we trust immunohistochemistry? Revisited f Pathol 1994; 172: 1-4
19. Hall PA, Meek D, Lane DP. p53 integrating the complexity. J Pathol 1996; 180: 19
20. Hurtt MR, Moossy J, Donovan-Peluso M et al. Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropatliol Exp Neurol 1992; 51: 84-90
21. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-9
22. Kleihues P, Burger PC, Scheithauer BW (Eds). Histological typing of tumors of the central nervous system ed 2. Berlin: Springer Verlag 1993
23. Kleihues P, Burger PC. Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol 1993: 3: 255-68
24. Kleihues P, Burger PC, Plate KH, Ohgaki H, Cavenee WK. Glioblastoma. Patliology and genetics tumours of nervous system. PI6-24. Edited by P. Kleihues and WK. Cavenee, International Agency for Research on cancer, Lyon 1995
25. Lang FF, Miller DC, Koslow M. Newcomb E\V. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neitrosurg 1994: 81: 427-36
26. Lax J, Burgess WH, Bellot F, Ullrich A, Schlessinger J, Givol D. Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Mol Cell Biol 1988; 8: 1831-4
27. Libermann TA, Nusbaum HR, Razon N et al. Amplification enhanced expression and possible rearrangement of EGFReceptor gene in primary brain tumours of glial origin. Nature 1985; 313: 144-7
28. Libermann TA, Razon N, Bartal AD et al. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res 1984; 44: 753-60
29. Louis DM. The p53 gene and protein in human brain tumors. J Neurosurg 1994; 81: 427-36
30. Ohgaki H, Schäuble B, Zur Hausen A, Von Ammon K, Kleihues P. Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch 1995:427: 113-8
31. Quigley MR, Maroon JC. The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 1991: 29: 385-9
32. Raghavan R. Steart PV. Weiler RO. Cell proliferation patterns in the diagnosis of astrocytomas, anaplastic astrocytomas and glioblastomas multiform: a Ki67 study. Neiiropatlwl Appl Neurobiol 1990; 16: 123-33
33. Rainov NG, Dobberstein KU, Bahn H et al Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor suppressor gene products on survival. J Neuro Oncol 1997; 35: 13-28
34. Rasheed BKA, McLendon RE, Herndon JE et al Alterations of the TP53 gene in human gliomas. Cancer Res 1994; 54: 1324-30
35. Rubio MP, Von Deimling A. Yandell DW, Wiestler OD, Gusella JF, Louis DN. Accumulation of wild type p53 protein in human astrocytomas. Cancer Res 1993; 53: 3465-7
36. Sallinen SL, Sallinen P, Haapasalo H et al. Accumulation of genetic changes is associated with poor prognosis in grade II astrocytomas. Am J Pathol 1997; 151: 1799-807
37. Schlegel J, Merdes A, Stumm G et al. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 1994; 56: 72-7
38. Shapiro WR, Green SB, Burger PC et al Randomized trial of three chemotherapy regimens and two radiotherapy regimen in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group trial 8001. J Neiirosurg 1989; 71: 1-9
39. Takasaki Y, Deng JS, Tan EM. A nuclear antigen associated with cell proliferation and blast transformation: its distribution in synchronized cells. J Exp Med 1981; 154: 1899-909
40. Torp SH, Helseth E, Dalen A, Unsgaard G. Relation ships between KI67 labeling indes amplification of the epidermal growth factor receptor gene and prognosis in human glioblastomas. Ada Neurochir 1992; 117: 182-6
41. Verheijen R, Kuipers HJH, Schlingemann RO et al. Ki67 detects a nuclear matrix-associated proliferation - related antigen. J Cell Sci 1989; 92: 123-30
42. Waha A, Baumann A, Wolf HK et a]. Lack of prognosis relevance of alterations in the epidermal growth factor receptor-transforming growth factor-a pathway in human astrocytic gliomas. J Neiirosurg 1996; 85: 634-41
43. Watanabe K. Tachibana 0. Sato K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGFR receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6:217-24
44. Winger MJ. Macdonald DR. Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent resection and prior low-grade glioma. J Neiirosurg 1989; 71: 487-93
45. Wong AJ, Bigner SH, Grezeschik CH, Humphrey PA, Bigner DS. Structural alterations of the epidermal growth factor receptor gene in human gliomas. PNAS 1992; 89: 2965-9
46. Zuber P, Hamou MF, De Tribolet N. Identification of the proliferating cells in human gliomas using the monoclonal antibody Ki67. Neiirosurnerij 1988; 22: 364-8